PIK3CA and neoplasm: There were three studies reported PFS concerning PIK3CA mutant status in archival or newly collected tumor issue, random-effect model (P = 0.07, I2 = 57%) showed that there was not statistically significant difference in PFS between combination therapy and the comparator (HR = 0.70, 95%CI: 0.48–1.02).